Recent Updates in Relapsed or Refractory Multiple Myeloma

Key opinion leaders discuss recent updates in treating relapsed or refractory multiple myeloma.

EP. 1: Risk of Myeloma Relapse After Frontline Therapy

June 4th 2021

Myeloma experts, Drs James Hoffman and Joshua Richter, discuss the factors that increase a patient’s risk of relapse after frontline treatment for multiple myeloma.

EP. 2: Newly Approved Regimens for Relapsed/Refractory Multiple Myeloma

June 4th 2021

Key opinion leaders discuss newly approved agents and their impact on treatment decisions for relapsed/refractory multiple myeloma.

EP. 3: Clinical Data for Selinexor Use in Myeloma

June 11th 2021

Experts in treating multiple myeloma discuss the trials that led to the approval of selinexor with bortezomib and dexamethasone, and which patient population would benefit from treatment, as well as the dosing, safety, and efficacy.

EP. 4: Evolving Treatment Options for Relapsed/Refractory Multiple Myeloma

June 11th 2021

Drs Hoffman and Richter discuss a promising new treatment for patients with relapsed/refractory multiple myeloma who are not eligible for a clinical trial after 4 lines of therapy.

EP. 5: Analysis of the BOSTON Trial

June 18th 2021

Experts in the field of multiple myeloma discuss the BOSTON trial, the study design, and the benefits of using selinexor in a patient after CAR T-cell therapy.

EP. 6: Selecting Appropriate Therapy for Patients With Relapsed/Refractory Multiple Myeloma

June 18th 2021

James Hoffman, MD, and Joshua Richter, MD, discuss the IKEMA study, the appropriate selection of therapy, and the differences between various options.

EP. 7: Considering Patient-, Treatment-, and Disease-Related Factors in Myeloma

June 25th 2021

Factors to consider when choosing the optimal treatment approach after the first relapse of multiple myeloma.

EP. 8: What’s Coming Next in Relapsed/Refractory Multiple Myeloma

June 25th 2021

Key opinion leaders remark about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.